BioVie Invited to Present Data on Bezisterim at NIH's RECOVER-TLC Workshop
BioVie Inc. has been invited to present clinical data on its investigational therapy, bezisterim, at the 2026 RECOVER–Treating Long COVID (RECOVER-TLC) Hybrid Workshop.
Stocks · News reference
Nasdaq Down 50 Points; US Foods Posts Upbeat Earnings
US stocks trade mixed, Nasdaq falls 50 points. Energy shares up 1.3%, tech stocks down 0.5%. US Foods beats earnings, Clearone Inc surges 203%.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BioVie shares are trading higher after the company announced the presentation of Phase 2 Long COVID data showing statistically significant improvements in fatigue and cognitive measures in certain patient subgroups treated with bezisterim.
BioVie Reports Data From Phase 2 ADDRESS-LC Trial Of Bezisterim At 151st Annual Meeting Of American Neurological Association
BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the presentation of
BioVie To Present Phase 2 Bezisterim Data In Long COVID, Parkinson’s At Neurology Conference October 18-19
Dow Surges Over 200 Points; Verizon Shares Fall Following Q3 Results
U.S. stocks rose Monday, led by the Dow’s 200-point gain. Consumer discretionary rallied, Verizon fell after mixed results, and oil dropped 1.2%.
8-K filing — CLEARONE INC (CLRO)
Filed: 2026-10-15 AccNo: 0001753926-26-001940 Size: 217 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Financial Statements and Exhibits